Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices loomsnews2025-11-25T17:32:39+00:00November 25th, 2025|Endpoints News|
FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 programnews2025-11-25T15:50:45+00:00November 25th, 2025|Endpoints News|
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trialnews2025-11-25T14:31:02+00:00November 25th, 2025|Endpoints News|
Novartis plans to lay off 550 workers at Swiss factory news2025-11-25T14:18:48+00:00November 25th, 2025|Endpoints News|
FDA approves Novartis’ Itvisma for older patients with spinal muscular atrophynews2025-11-25T12:09:26+00:00November 25th, 2025|Endpoints News|
Novartis was the sole bidder in $12B deal to buy Aviditynews2025-11-25T09:00:28+00:00November 25th, 2025|Endpoints News|
FDA’s Pazdur is said to raise questions about commissioners actions, new vouchernews2025-11-24T21:04:48+00:00November 24th, 2025|Endpoints News|
UK-US drug pricing deal could come as early as this week, sources saynews2025-11-24T20:53:12+00:00November 24th, 2025|Endpoints News|
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 winsnews2025-11-24T20:51:46+00:00November 24th, 2025|Endpoints News|
J&J’s tau-targeting antibody fails Phase 2 Alzheimer’s studynews2025-11-24T16:22:48+00:00November 24th, 2025|Endpoints News|
